Eli Lilly lifts guidance by $10 billion as GLP‑1 sales outpace expectations

Eli Lilly said its latest financial guidance is $10 billion higher than previously forecast, driven by strong sales of its GLP‑1 medicines. The company’s commercial performance has repeatedly exceeded analyst expectations, prompting the upward revision.

During the earnings call, CEO David Ricks explained that the rapid growth of the incretin market is unprecedented and difficult to predict. He noted that Lilly is now the leader in what he described as the largest new therapeutic category expansion in pharma history.

Analysts on the call acknowledged the surprise factor in the guidance, with some questioning how long the outsized growth can continue. Despite the uncertainty, the overall tone was positive, reflecting confidence in the company’s pipeline and its ability to sustain momentum.

Lilly’s management also hinted at pursuing earlier business‑development opportunities to build a longer‑term pipeline, leveraging the cash flow generated by the GLP‑1 success.